OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
August 07, 2020
The European Medicines Agency recently approved two European Novartis sites in France and Switzerland for the commercial manufacturing of chimeric antigen receptor T-cell cell therapies.
August 06, 2020
The expansion will involve using the facilities’ existing central utilities and labs to supplement its small-scale and large-scale assets.
The expanded facility will feature two new 40-L and 300-L manufacturing vessels, a capsule filling line, and six drying tunnels that will add more than 10 million doses per annum to the site.
August 03, 2020
The investment will allow for the expansion of analytical R&D efforts and will support the company’s reference materials business.
August 01, 2020
Filling and packaging of primary containers is a crucial piece of COVID-19 vaccine production.
July 08, 2020
The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.
July 07, 2020
The new site will offer initial design and development, low-volume manufacturing, and scalable high-quality production of wearable drug delivery devices.
July 02, 2020
The new facility in Grand Rapids, MI, is part of the CDMO’s aggressive expansion plan.
July 01, 2020
Manufacturers must address scale-out challenges of autologous cell therapy for commercial manufacturing.
June 30, 2020
The expansion included adding new softgel encapsulation lines at its Strathroy, Canada and Sorocaba, Brazil sites for Catalent’s Vegicaps plant-based capsule and its CosmoPod twist-off capsule technologies.